← Back to Search

Alpha-1 Adrenergic Receptor Antagonist

Prazosin for Cannabis Use Disorder (ReCOUP Trial)

Phase 4
Recruiting
Led By Garth E Terry, MD, PhD
Research Sponsored by VA Puget Sound Health Care System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 to 80 years inclusive
Men, women, and persons of all races and ethnic backgrounds are eligible.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

ReCOUP Trial Summary

This trial will study whether the drug prazosin, which is used to treat symptoms of PTSD, can also help reduce cannabis use disorder in people who have PTSD.

Who is the study for?
This trial is for adults aged 18-80 who use cannabis at least four days a week and want to reduce their usage. They must be in good health, not using substances other than tobacco or alcohol, and agree to birth control if applicable. Those with PTSD symptoms may benefit especially.Check my eligibility
What is being tested?
The study tests Prazosin Hydrochloride's ability to help individuals with or without PTSD reduce cannabis overuse by treating symptoms like insomnia and nightmares that often lead them to use cannabis.See study design
What are the potential side effects?
Prazosin may cause dizziness, headache, drowsiness, lack of energy, weakness, palpitations, nausea or vomiting. It can also potentially lead to low blood pressure upon standing up which might result in fainting.

ReCOUP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old.
Select...
I am of any gender and ethnic background.
Select...
I am between 18 and 80 years old.
Select...
I can complete health assessments in English.

ReCOUP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability of participation
Quantifying cannabis consumption
Recruitment
+1 more
Secondary outcome measures
Treatment outcome (exploratory)

Side effects data

From 2016 Phase 1 trial • 20 Patients • NCT01999530
30%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Prazosin Hydrochloride

ReCOUP Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-label prazosin treatmentExperimental Treatment1 Intervention
Open-label administration of prazosin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prazosin Hydrochloride
2013
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

VA Puget Sound Health Care SystemLead Sponsor
63 Previous Clinical Trials
227,713 Total Patients Enrolled
University of WashingtonOTHER
1,732 Previous Clinical Trials
1,842,094 Total Patients Enrolled
VA Mental Illness Research, Education and Clinical CentersFED
1 Previous Clinical Trials
35 Total Patients Enrolled

Media Library

Prazosin Hydrochloride (Alpha-1 Adrenergic Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04721353 — Phase 4
Cannabis Use Disorder Research Study Groups: Open-label prazosin treatment
Cannabis Use Disorder Clinical Trial 2023: Prazosin Hydrochloride Highlights & Side Effects. Trial Name: NCT04721353 — Phase 4
Prazosin Hydrochloride (Alpha-1 Adrenergic Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04721353 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other research has been performed on Prazosin Hydrochloride?

"Currently, 7 clinical trials are underway exploring the efficacy of Prazosin Hydrochloride. Of these studies, 1 is in Phase 3. While most experiments for this medication occur in Seattle Washington, there are 9 total sites running relevant research projects."

Answered by AI

Does this research project permit participation from individuals under 25 years of age?

"The age range for participants in this trial is between 18 and 80. As expected, there are fewer trials available for those below the legal age of consent (298) when compared to individuals aged 65 or above (906)."

Answered by AI

What is the common application for Prazosin Hydrochloride?

"Prazosin Hydrochloride is prescribed to address post traumatic stress disorder (PTSD). It may also be helpful in managing hypertension, disturbing dreams and benign prostatic hyperplasia (BPH)."

Answered by AI

What is the upper limit on participants for this clinical trial?

"Affirmative. Clinicaltrials.gov records indicate that this trial, which was originally published on November 9th 2020, is currently recruiting participants. Twenty individuals are required between a single medical site."

Answered by AI

Are researchers currently accepting new participants for this research endeavor?

"Affirmative. The details on clinicaltrials.gov specify that this scientific experiment, which was first shared 11/9/2020, is currently enrolling volunteers. This project requires 20 participants from a single medical facility to be recruited for the trial."

Answered by AI

What are the eligibility requirements to be part of this experimental research?

"This clinical trial is searching for 20 individuals, aged between 18 and 80, who have experienced stress disorders or trauma. Furthermore, the study welcomes males, females and all racial backgrounds; provided they are in good health overall."

Answered by AI

What potential adverse effects can arise from taking Prazosin Hydrochloride?

"Data collected from Phase 4 trials indicates that Prazosin Hydrochloride is safe, granting it a rating of 3."

Answered by AI

Who else is applying?

What state do they live in?
Washington
How old are they?
18 - 65
What site did they apply to?
VA Puget Sound Health Care System
What portion of applicants met pre-screening criteria?
Met criteria
~4 spots leftby Dec 2024